Relation of Red Cell Distribution Width with Thromboembolic Risk in Patients Had Non-valvular Atrial Fibrillation

被引:0
|
作者
Ahmed, Ibrahim Elsayed [1 ]
Naguib, Tarek Ahmed [1 ]
Elzyat, Ahmed Mohamed [1 ]
Mohamed, Shimaa Wageeh [1 ]
机构
[1] 6 Ahmed Ismaeel St, Cairo, Egypt
关键词
non-valvular atrial fibrillation; thrombo-embolism; CHA2DS2-VASc;
D O I
暂无
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Higher red blood cell distribution width (RDW) anticipates harmful events among patients have cardio-vascular diseases. On other hand, there is imperfect information concerning the association between RDW and thrombo-embolism hazard in the patients with atrial fibrillation. We intended to study the relation between RDW and CHA2DS2-VASc scores which utilized for assessment of thrombo-embolic hazard in patients with non-valvular AF. Our study enrolled 46 patients with AF. We calculated CHA2DS2-VASc score for every patient, and we investigate the laboratory and echocardiographic parameters. Depend on CHA2DS2-VASc scores; we classified the AF patients into two groups (low - intermediate risk and high risk groups). Then, we compared mentioned parameters between the 2 groups, and we assessed the relation between RDW and CHA2DS2-VASc score. Multivariate regression analysis was done to find independent predictors of high CHA2DS2-VASc scores. Patients with elevated CHA2DS2-VASc scores had older age and higher RDW, hs-CRP, creatinine serum level, left atrial diameter and intervetricular septum thickness comparably to low CHA2DS2-VASc score group. Multivariate regression analysis appeared that RDW and hs-CRP were independent predictors for high CHA2DS2-VASc scores. RDW is significantly associated with CHA2DS2-VASc score among patients have AF. Furthermore, RDW considers an independent predictor in CHA2DS2-VASc score.
引用
收藏
页码:1192 / 1198
页数:7
相关论文
共 50 条
  • [41] Cardioversion in Non-Valvular Atrial Fibrillation
    Klein, Hermann H.
    Trappe, Hans-Joachim
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2015, 112 (50): : 856 - +
  • [42] RISK OF THROMBOEMBOLISM IN NON-VALVULAR ATRIAL FIBRILLATION AND ADEQUACY OF ANTICOAGULATION IN HIGH RISK PATIENTS
    Farooq, Fawad
    Hashim, Muhammad
    Khalid, Muhammad Rahman
    Karim, Musa
    PAKISTAN HEART JOURNAL, 2018, 51 (04): : 314 - 318
  • [43] Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation
    Zhu, Zhu
    Shen, Zhu
    Shi, Aiming
    Su, Cunjin
    Mao, Jiaojiao
    Tao, Hong
    Xu, Feng
    Hu, Zhanhong
    Pan, Jie
    HEART AND VESSELS, 2022, 37 (05) : 821 - 827
  • [44] Warfarin utilization and stroke risk in patients with chronic non-valvular atrial fibrillation
    Boccuzzi, SJ
    Stephenson, JJ
    Kreilick, CA
    Beaulieu, JF
    Hauch, O
    Kim, J
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 335A - 335A
  • [45] Analysis of the influence of thromboembolic complications prevention with oral anticoagulants on budget in patients with non-valvular atrial fibrillation
    Rudakova, A. V.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2015, 11 (03) : 267 - 271
  • [46] Left atrial appendage occlusion in high-risk patients with non-valvular atrial fibrillation
    Berti, Sergio
    Pastormerlo, Luigi Emilio
    Rezzaghi, Marco
    Trianni, Giuseppe
    Paradossi, Umberto
    Cerone, Elisa
    Ravani, Marcello
    De Caterina, Alberto Ranieri
    Rizza, Antonio
    Palmieri, Cataldo
    HEART, 2016, 102 (24) : 1969 - 1973
  • [47] IMPROVEMENT IN THROMBOEMBOLIC OUTCOMES WITH WARFARIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION OVER THE LAST TWO DECADES
    Agarwal, Shikhar
    Hachamovitch, Rory
    Menon, Venu
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E1836 - E1836
  • [48] Role of homocysteine for thromboembolic complication in patients with non-valvular atrial fibrilation
    Cingozbay, BY
    Yiginer, O
    Cebeci, BS
    Kardesoglu, E
    Demiralp, E
    Dincturk, M
    BLOOD COAGULATION & FIBRINOLYSIS, 2002, 13 (07) : 609 - 613
  • [49] Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry
    Vene, Nina
    Mavri, Alenka
    Gubensek, Mirjam
    Tratar, Gregor
    Cuderman, Tjasa Vizintin
    Perme, Maja Pohar
    Blinc, Ales
    PLOS ONE, 2016, 11 (06):
  • [50] Which method of left atrium size quantification is the most accurate to recognize thromboembolic risk in patients with non-valvular atrial fibrillation?
    Faustino, Ana
    Providencia, Rui
    Barra, Sergio
    Paiva, Luis
    Trigo, Joana
    Botelho, Ana
    Costa, Marco
    Goncalves, Lino
    CARDIOVASCULAR ULTRASOUND, 2014, 12